The other side of TNF-targeted therapy of patients with rheumatoid arthritis Tohru AbeTsutomu Takeuchi Invited Commentary Pages: 1 - 2
Identification of crystals in synovial fluids and joint tissues Ann K. RosenthalNeil Mandel OriginalPaper Pages: 11 - 16
Pathogenesis of calcium pyrophosphate crystal deposition disease Ann K. Rosenthal OriginalPaper Pages: 17 - 23
Phosphocitrate as a potential therapeutic strategy for crystal deposition disease Herman S. Cheung OriginalPaper Pages: 24 - 28
Difficult gout and new approaches for control of hyperuricemia in the allopurinol-allergic patient Adel G. Fam OriginalPaper Pages: 29 - 35
Pathogenesis of crystal-induced inflammation R. Clive LandisDorian O. Haskard OriginalPaper Pages: 36 - 41
Radiography of rheumatoid arthritis in the time of increasing drug effectiveness Frederick WolfeVibeke Strand OriginalPaper Pages: 46 - 52
Can we induce tolerance in rheumatoid arthritis? Arnold E. Postlethwaite OriginalPaper Pages: 64 - 69
Apoptosis and rheumatoid arthritis: Past, present, and future directions John D. MountzHui-Chen HsuHuang-Ge Zhang OriginalPaper Pages: 70 - 78
Gene therapy for rheumatoid arthritis Elvire GouzeSteven C. GhivizzaniChristopher H. Evans OriginalPaper Pages: 79 - 85
Relationship between time-integrated C-reactive protein levels and radiologic progression in patients with rheumatoid arthritis Larry W. Moreland Clinical Trials Report Pages: 92 - 92